Weight regain reality: what the clinical data shows Before diving into restart protocols, you need to understand what the research says about weight regain after stopping semaglutide
Unlike a bottle of pills you can toss into a bag and forget about, injectable tirzepatide demands awareness of its environment at every stage of your journey
These new diabetes and weight loss medicines mimic a natural gut hormone called GLP-1 that has three main functions boosting insulin, slowing the emptying of the stomach and acting on parts of the brain that regulate hunger
Its also possible that some aspects of the drugs compounds could directly act on specific food preferences through some other biological mechanism
The net effect is simple: After weight loss, people are hungrier, feel less satisfied after eating and burn fewer calories than expected
These data are a cornerstone in our research and build on our understanding of how MASH and cardiometabolic conditions like type 2 diabetes, obesity, dyslipidemia [abnormal fat levels in the blood], and high blood pressure are interrelated. Metabolic dysfunction-associated steatotic liver disease (MASLD), occurs when abnormal amounts of fat accumulate in the liver in the presence of cardiometabolic risk factors such as type 2 diabetes, obesity, high blood levels of cholesterol or other fats, or high blood pressure
,aspect=ignore)
